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Abstract: Neurological diseases represent a medical, social, and economic problem of para-
mount importance in developed countries. Although their etiology is generally known, developing 
therapeutic interventions for the central nervous system is challenging due to the impermeability 
of the blood–brain barrier. Thus, the fight against neurological diseases usually struggles “at the 
gates” of the brain. Flooding the bloodstream with drugs, where only a minor fraction reaches 
its target therapeutic site, is an inefficient, expensive, and dangerous procedure, because of the 
risk of side effects at nontargeted sites. Currently, advances in the field of nanotechnology have 
enabled development of a generation of multifunctional molecular platforms that are capable 
of transporting drugs across the blood–brain barrier, targeting specific cell types or functional 
states within the brain, releasing drugs in a controlled manner, and enabling visualization of 
processes in vivo using conventional imaging systems. The marriage between drug delivery and 
molecular imaging disciplines has resulted in a relatively new discipline, known as theranostics, 
which represents the basis of the concept of personalized medicine. In this study, we review 
the concepts of the blood–brain barrier and the strategies used to traverse/bypass it, the role of 
nanotechnology in theranostics, the wide range of nanoparticles (with emphasis on liposomes) 
that can be used as stealth drug carriers, imaging probes and targeting devices for the treatment 
of neurological diseases, and the targets and targeting strategies envisaged in the treatment of 
different types of brain pathology.
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The CNS and blood–brain barrier: “the enemy 
at the gates”
Neurological diseases represent a medical, social, and economic problem of paramount 
importance in developed countries, in particular because their incidence is increasing 
rapidly with the progressive rise in life expectancy.1
Although the etiology of most neurological diseases is known and experimental 
studies have continuously provided potential drugs for their treatment, the performance 
of therapeutic interventions in the central nervous system (CNS) remains a challenge. 
The CNS is a complex and vulnerable system, and its evolution has provided it with 
effective mechanisms of defense against foreign elements. Ironically, the strength 
of these defensive mechanisms usually complicates attempts to perform therapeutic 
interventions within the CNS.2 Thus, the fight against neurological diseases usually 
struggles “at the gates” of the brain.
There are three main barriers that regulate molecular exchange between the blood and 
brain parenchyma, including the blood–brain barrier, which is formed by the interaction 
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between glial cells and endothelial cells of the blood vessels in 
the brain, the choroid plexus epithelium, which is the border 
between the blood and ventricular cerebrospinal fluid, and 
the arachnoid epithelium, which separates the blood from the 
subarachnoid cerebrospinal fluid.
The blood–brain barrier represents the main gateway via 
which systemically administered drugs access the brain and 
is the structural basis of the functional system known as 
the neurovascular unit, which is formed by a monolayer of 
endothelial cells connected to each other via tight junctions, 
as well as by astrocytic end feet, perivascular neurons, 
and pericytes (Figure 1).3,4 Endothelial cells of the brain 
are highly polarized and show low pinocytic activity, but 
contain different active transport mechanisms to ensure 
homeostasis of the brain. Endothelial cells also contain 
large concentrations of P-glycoprotein. P-glycoprotein is 
an ATP-dependent protein that actively transports a wide 
range of drugs out of the brain. P-glycoprotein inhibits 
penetration of relatively large (.400 Da) hydrophobic 
drugs into the brain via active back transport of these drugs 
into the blood.5
Thus, the blood–brain barrier is permeable to small 
and lipophilic molecules (eg, oxygen, carbon dioxide, and 
nicotine) and larger molecules which do not spontaneously 
diffuse across it and must be transported across the blood–
brain barrier via specific carrier systems (ie, systems used for 
transport of glucose and essential amino acids) or by receptor-
mediated endocytosis systems (eg, systems used for leptin, 
transferrin, or insulin) which are present in the membrane 
of the endothelial cell (Figure 1). For those molecules that 
cannot make use of one of the aforementioned transport 
mechanisms, different strategies can be used to transport 
these molecules into the brain parenchyma to reach the site 
of pathology.
One way to circumvent the blood–brain barrier is direct 
administration of an intraparenchymal injection of the 
desired substance. Another is to use implantable systems, 
such as osmotic pumps or enhanced convention devices, 
for continuous drug infusion. However, surgical approaches 
are invasive, risky, and cannot be used when the implantable 
device crosses or targets critical areas of the brain. It is also 
possible to use such devices to perform intraventricular 
or intrathecal administration of drugs when involving the 
cerebrospinal fluid-brain barrier to avoid the blood–brain 
barrier. Intranasal delivery is also an emerging noninvasive 
alternative to bypass the blood–brain barrier and facilitates 
delivery of large charged therapeutic molecules into the 
brain.7
Rather than bypassing the blood–brain barrier, it is 
possible to disrupt it temporarily by opening the tight 
junctions of endothelial cells. Under these conditions, 
permeability of the blood vessels in the brain to systemically 
applied treatments can be increased.8 A transient disruption of 
the blood–brain barrier may be achieved by: osmotic shock 
using mannitol, arabinose, or other hypertonic solutions; 
acting at specific receptors on endothelial cells with substrates 
that affect the tight junctions, such as bradykinin receptors;9 
and using magnetic resonance imaging-guided ultrasound in 
combination with microbubbles of contrast agents to induce 
focalized openings in small areas of the brain.10 Opening 
of the blood–brain barrier may be a dangerous procedure 
because it can cause hydroelectrolytic changes and suppress 















































Figure 1 (A) Structure of the blood–brain barrier, established by the endothelial cells of blood capillaries and their tight junctions (B) Different mechanisms for the 
transporting of substances across the blood–brain barrier. Adapted from Mol Med Today, 2, Abbott NJ, Romero IA, Transporting therapeutics across the blood-brain barrier. 
106–113. Copyright (1996), with permission from Elsevier.6
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There are alternative methods for distributing drugs 
inside the brain parenchyma without altering the blood–brain 
barrier when the aforementioned transport mechanisms are 
not suitable or unavailable. The first option is to use chemical 
derivatives or to partially modify the structure of the drug 
to facilitate traversing of the blood–brain barrier while 
maintaining drug activity (eg, by adding aliphatic chains 
to increase lipophilicity).13 A second possibility is to use 
prodrugs, ie, reversible compounds that in their native state are 
not biologically active, but are able to cross the blood–brain 
barrier and undergo an enzymatic or chemical transformation 
once in the brain parenchyma, thereby becoming active.14
The most versatile and attractive approach for delivery of 
drugs in their native state into the brain parenchyma involves 
use of drug carriers as “Trojan horses”, ie, nanoscaled 
molecular platforms carrying therapeutic compounds that can 
cross the blood–brain barrier. In this context, nanotechnology 
represents a key component in the development of effective 
treatments for diseases of the CNS.
Multiple structures have been proposed for drug delivery 
in recent years. In general, there are two large families of 
transporters, ie, reversible and irreversible nanoparticles. 
Reversible nanoparticles are supramolecular complexes 
generated on the basis of noncovalent intermolecular 
interactions, ie, Van der Waals forces or lipophilic 
interactions. Liposomes and micelles are the most well 
known examples of these types of nanoparticles (Figure 2). 
These are molecules formed by noncovalent binding of 
their components which can self-assemble spontaneously 
and reversibly into organized structures under specific 
environmental conditions, eg, temperature, pH, and polarity 
of the medium.15 Changes in environmental conditions 
usually result in disaggregation of the molecular units that 
form the particle. This may represent an advantage, eg, 
enabling release of a drug load in specific environments, 
such as a sudden drop in tissue pH, as occurs in ischemic 
brain tissue after lactic acidosis, or be a disadvantage, eg, 
the molecule may disintegrate before reaching its target. 
Disaggregation of the nanoparticle components may be 
reversed by returning to the original conditions that favor 
their self-aggregation. Reversible nanoparticles are extremely 
versatile and malleable structures, easy to prepare in 
nonspecialized laboratories, and are the basis of preparation 
of new pharmaceutical approaches to the treatment of CNS 
disorders in neuroscience research laboratories. However, 
the unstable nature of these systems makes them less 
suitable for preparation of stable commercial products by 
the pharmaceutical industry.16
Conversely, the broad family of nonreversible 
nanoparticles (including dendrimers, nanocapsules, 
nanospheres, nanocages, and nanotubes, Figure 2) comprises 
molecules with strong molecular interactions, eg, covalent 
or metallic bonds, which confer a high degree of stability, 
thereby facilitating their manufacturing for commercial 
purposes, but are more rigid in their synthesis and handling. 
The preparation of these types of particles is less common 
in neuroscience research laboratories unless there is 
collaboration with specialized material science laboratories 
(a powerful coalition that is becoming quite common).
It is beyond the scope of this review to describe these 
structures or analyze the advantages and disadvantages of 
each of these molecules further, and the reader is referred to 
an excellent review by Vlieghe and Khrestchatisky13 for this 
purpose. Instead, we will focus on the use of these molecules 
to target the CNS.
At the dawn of the second millennium, advances achieved 
in the field of nanotechnology enabled us to build complex 
functionalized macromolecules that not only have optimized 
loading and release characteristics to carry and deliver 
therapeutic agents to the CNS in a controlled manner but 
also confer stealth capabilities to increase circulation time 
in the bloodstream, avoiding agglutination of the agent with 
plasmatic proteins or its retention in the liver, spleen, or 
other nonpathological organs, such as the lungs, enable 
targeting of specific tissues or cells, and include imaging 
probes for in vivo follow-up of these processes. The most 
exciting advance in recent years has been the possibility 
Drug Micelle Liposome
Nanosphere Nanocapsule Dendrimer
Figure 2 Schematic representation of different particulate systems for drug 
transport and delivery. 
Notes: Some of these systems include self-assembling molecules, such as liposomes 
and micelles, while others are based on nonreversible organic or inorganic structures, 
such as nanospheres, nanocapsules, and dendrimers.
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of performing all these tasks under the same molecular 
platform, which together are known as “theranostics”.
Liposomes and nanotechnology 
in theranostics: “veni, vidi, vici”
Theranostics is a relatively new discipline in the context of 
personalized medicine, and involves use of nanotechnology 
to assemble molecular platforms that simultaneously perform 
a therapeutic and diagnostic function.17 Alternatively, we can 
define theranostics in reference to the famous Latin quotation 
“veni, vidi, vici” (meaning “I came, I saw, I conquered”) 
from Julius Caesar in the year 47 BC, when commenting on 
his victorious campaign against Pharnaces II of Pontus. In 
this section, we describe how nanotechnology is essential to 
achieve the main goal of theranostics, ie, “to come, to see, 
and to conquer” disease.
“veni”: theranostic agents for targeted 
delivery
The most important characteristic of a theranostic agent is 
its ability to target the site of pathology. Most neurological 
disorders are focal and only affect a particular organ or 
tissue, eg, brain, spine, or peripheral nerves, or a region 
within the tissue (Figure 3A). Sometimes only specific cell 
types, eg, dopaminergic neurons of the substantia nigra in 
Parkinson’s disease, or cells in a particular functional state, 
eg, apoptotic cells in the post-ischemic brain, are affected. 
Thus, systemic administration of treatment involves delivery 
of a drug throughout the body, in the hope that a sufficient 
fraction of the drug will reach the region/tissue where it is 
required (Figure 3B).
Systemic administration of drugs is inefficient, in that 
most of the drug ends up in a place where it is not required 
or is excreted, and is often accompanied by harmful side 
effects in nonpathological tissues, eg, several glutamate 
receptor agonists have shown a neuroprotective effect 
against ischemia in the laboratory but are not effective for 
the treatment of stroke in humans because of unacceptable 
side effects. Thus, it is convenient to identify strategies that 
facilitate concentration of active principles at the site of the 
disease, minimizing their presence in other tissues or regions 
of the body where they are not needed. This concept is known 
as targeted drug delivery (Figure 3C).
Theranostic agents are molecular platforms (such as 
liposomes, micelles, dendrimers, and nanospheres) that can 
be used as drug carriers to solubilize, stabilize, protect, and 
ultimately deliver therapeutic drugs in a controlled manner. 
These carriers may include “molecular antennae” such 
as antibodies and aptamers on their surface which allow 
them to interact specifically with target cells via molecular 
recognition mechanisms (Figure 4).
Indeed, cells that express specific molecular markers on 
their membranes can be used to specify their origin, phenotype, 
and functional status, ie, using immunohistological studies, 
blotting, or flow cytometry techniques. Immunovectorization 
of macromolecules against selected biomarkers enables 
“identification” of target cells and delivery of therapeutic 
agents only to targeted areas (Figure 4).18
Figure 3 Concept of theranostics. (A) A pathological process localized to the brain. (B) Systemic administration of a therapeutic agent distributes the theranostic throughout 
the entire body. (C) Nanotechnology enables concentration of the agent in the targeted area. (D) Inclusion of imaging probes within the agent enables monitoring of the 
process in vivo. (E) By focusing the action of the therapeutic agent in the targeted area, the treatment becomes more effective.
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A systematic and indepth review of the approaches 
available for crossing the blood–brain barrier is beyond the 
scope of this work, and the reader is referred to a review by 
Vlieghe and Khrestchatisky13 for this purpose.
“vidi”: theranostic molecules 
for diagnosis
A second requirement for a theranostic agent is inclusion of 
imaging probes on its surface, enabling its detection using 
different imaging technologies (Figure 4). In this way, the 
presence of the theranostic (and ultimately therapeutic) 
agent in the targeted area is ensured, and visualization of its 
spatiotemporal dynamic accumulation in the areas required is 
possible. The presence of imaging probes also facilitates the 
location, delineation, and quantification of affected tissues 
(ie, theranostic agents have a diagnostic function) and enables 
monitoring of progression of the pathological process in 
response to treatment on an individual basis (Figure 3D), 
which is a fundamental principle of personalized medicine.
In this context, and as a result of the macromolecular 
nature of theranostic agents, it is possible to include more 
than one type of imaging probe using multiple imaging 
techniques. Thus, it is common for theranostic agents to 
contain iron oxide particles or gadolinium chelates for 
their in vivo detection using magnetic resonance imaging, 
along with radioactive isotopes for detection using positron 
emission tomography or single photon emission computed 
tomography, and fluorescence probes, quantum dots, or 
bioluminescent probes for detection using fluorescence or 
optical imaging techniques. Multimodal imaging probes 
enable maximal exploitation of the advantages of each of 
these techniques, ie, the sensitivity and specificity of positron 
emission tomography, the spatial and temporal resolution 
of magnetic resonance imaging, and the microscopic 
resolution of fluorescence microscopy. Figure 5 shows a 
T1-weighted magnetic resonance image of a rat brain (at 9.4 
Tesla) on the left side which was acquired one hour after an 
intraparenchymal injection of gadolinium-doped liposomes 
(their composition has been described elsewhere)19 and 
produced a hyperintense signal via reduction of T1 relaxation 
time in the tissue. On the right is a fluorescence microscopic 
image of brain tissue from the same animal, showing red 
fluorescence in the cytoplasm of some cells (liposomes 


























Figure 4 Theranostic agents in molecular recognition processes. (A) A liposomal theranostic agent includes surface antibodies that participate in the molecular recognition 
process with targeted cells, imaging probes (for diagnostic purposes), and active principles of treatment. (B) Targeting of specific cells occurs via expression of specific surface 
receptors against which theranostic agents are “immunized”. 
Note: Both immunized agents and expression of cell biomarkers (low-right corner) are required for the molecular recognition process.
Figure 5 Multimodal imaging of a theranostic agent. 
Notes: A color-coded in vivo magnetic resonance image of a rat brain, where the 
agent is indicated as a hyperintense area (shown on the left). An ex vivo fluorescence 
microscopic image of the brain tissue of the animal, indicating presence of the 
theranostic agent (red fluorescence) in the cytoplasm of some neurons but not in all 
(cellular nuclei are stained in blue), is shown on the right. (Images were obtained at 
our laboratories in Santiago de Compostela).
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tissue. Follow-up of the delivery process and the response 
of the targeted tissue to therapy enable dose modulation or 
treatment changes in nonresponders.
“vici”: theranostic molecules 
to treat disease
The ultimate role of a theranostic agent is to carry a drug, 
or a combination of drugs, to perform a therapeutic function 
and “conquer” a disease. As previously discussed, theranostic 
agents are advanced drug carriers and as such their structure 
is designed to contain an adequate load of a therapeutic agent 
to stabilize, transport, and release the drug in a controlled 
manner at its intended site of action. Several exciting 
examples of theranostic systems have now been reported in 
the literature in the treatment of cancer,20 atherosclerosis,21 
and gene delivery.22
Thus far, most of the reported applications for theranostics 
have involved the activity of macromolecular agents at a 
vascular level, eg, atherosclerosis, or in tissues with a high 
density of blood vessels, which usually have increased 
permeability, eg, tumors. There is little evidence of theranostic 
approaches being used to target areas located inside the brain 
parenchyma because of the difficulties faced by systemically 
administered substances in crossing the blood–brain barrier.23 
The multitasking nature of theranostic agents involves 
construction of complex nanostructures, which affect the 
capacity of more basic structures, ie, the drug carriers on 
which they are based, to cross the blood–brain barrier.
Increased size and changes in the charge and polarity 
of nanostructures are a more common cause of reduced 
blood–brain barrier permeability for these nanoplatforms, 
with respect to their simplified drug carriers. However, 
our research group and others have demonstrated that 
encapsulation of therapeutic agents in targeted theranostic 
molecules (for example, heat shock protein [HSP]72-
targeted liposomes)23 results in increased eff icacy in 
the treatment of neurological disorders such as stroke 
(Figure 6). The top row of Figure 6 shows a series of 
T1-weighted magnetic resonance images (at 9.4 Tesla) 
of the brains of three rats that were subjected to an 
experimental model of ischemia,19 with superimposed 
colored maps of changes in longitudinal relaxivity (R1) 
24 hours after intravenous injection of a therapeutic agent, 
cytidine diphosphate-choline (citicoline), in its free state 
(left), encapsulated in gadolinium-doped liposomes (center, 
composition described elsewhere by Ramos-Cabrer et al),19 
or encapsulated in the same liposomes with anti-HSP72 
antibodies attached to its surface to vectorize the liposomes 
to the peri-infarct region (right).23 Localization of the 
liposomes is possible because of their gadolinium load, 
given that gadolinium is a contrast agent that increases 
R1 relaxivity. The bottom row of the image shows 
pseudocolored magnetic resonance maps of transverse 
relaxation times (T2) for the same animals 7 days after 
treatment. The severity of the lesion (hyperintense on these 













Figure 6 Theranostic activity of an agent that targets the peri-infarct region in ischemic animals. 
Notes: Top row: T1 magnetic resonance images with superimposed colored maps of changes in relaxivity (R1) after intravenous injection of a therapeutic agent (citicoline) 
in its free state (left), encapsulated in regular liposomes (center), and in heat shock protein (HSP) 72-targeted liposomes (right). Localization of the liposomes is possible 
because of their load of gadolinium, a contrast agent that increases R1 relaxivity. Bottom row: pseudocolored magnetic resonance maps of transverse relaxation times (T2) 
in the same animals 7 days after treatment. The severity of the lesion is clearly reduced by targeted treatment. (Experiments performed in and magnetic resonance image 
obtained at our laboratories in Santiago de Compostela).
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Despite the challenges inherent in crossing the blood–
brain barrier, theranostics and nanotechnology are now 
providing exciting opportunities for development of novel 
treatments for neurological diseases. A good example of the 
powerful combination of both disciplines in this situation is 
the use of citicoline for the treatment of ischemic stroke. Our 
group19 and others24–29 have demonstrated that inclusion of 
citicoline in liposomes results in a considerable increase (by 
more than 10-fold) in the bioavailability of the drug in the 
brain parenchyma compared with the drug administered in 
its free form. Thus, the known therapeutic effect of this drug 
in the treatment of stroke is enhanced by its encapsulation 
in liposomes.19,24,25
Recent clinical trials have shown that citicoline is not 
effective for the treatment of stroke31–34 or traumatic brain 
injury35 when administered orally to patients. However, the 
conclusions of these trials may be flawed because citicoline 
delivered orally may simply not reach the target brain tis-
sue in sufficient concentrations to have beneficial effects. 
It is also possible that liposomal formulations of citicoline 
enable delivery of more intact drug into the brain, where it 
is able to have a therapeutic effect. Although a future clini-
cal trial with liposome-encapsulated citicoline may offer a 
second opportunity for this drug, performing such a study 
represents a huge challenge, requiring adequate resolu-
tion of practical questions, such as how to manufacture a 
stable and affordable liposomal formulation for use in the 
research setting.
Multiple concerns will need to be overcome before engi-
neered nanomaterials for targeted drug delivery can become a 
reality in everyday clinical practice. Issues such as large-scale 
production, cost-effectiveness, and the potential toxicity of 
new nanomaterials are hot topics in current state-of-the-art 
theranostics.
In particular, concerns regarding the potential inter-
actions of nanostructures with biological systems have 
given rise to an emerging subdiscipline of nanotechnol-
ogy known as “nanotoxicology”, which focuses on the 
potential relationships between the physical and chemical 
properties of nanostructures (such as size, shape, surface 
chemistry, composition, and aggregation) and induction 
of toxic biological responses in vivo. An indepth review 
of issues such as the interaction between nanostructures 
and biological systems, or the biodistribution, clearance, 
immune response, and metabolism of nanoparticles in vivo 
is beyond the scope of this paper, and the reader is referred 
to a good review by Fischer and Chan for further details 
on this subject.36
CNS disorders and targets:  
“to boldly go where no man 
has gone before”
Neurological diseases have different origins and evolutions, 
so nanotechnology is unable to propose a universal solution 
for their treatment, although there are suitable solutions 
available for each circumstance. Some diseases are localized 
to a specific area that can be delineated, eg, some brain 
tumors, whereas others are diffuse and less specific. Some 
neurological diseases require chronic treatment, while others 
require acute intervention. A different approach may even 
be necessary for the acute and chronic phases of the same 
disease. Under these circumstances, targeting strategies and 
selected technological approaches used to address them 
need to be chosen appropriately. In general, there are three 
potential targeting strategies that should be considered, 
depending on the nature of the neurological disorder.
Focal neurological disorders
Brain tumors, traumatic brain injury, hemorrhage, and 
ischemic stroke are common neurological disorders where 
the therapeutic target is a specific area of the encephalic 
mass. Sometimes the therapeutic target is the pathological 
tissue per se (as with malignancy), but it may also be located 
in the surrounding areas (eg, the peri-infarct region in 
ischemic stroke).23,37 In either case, there are two possible 
strategies for targeting the site of pathology. The first strategy 
involves magnetic vectorization of the therapeutic agent and 
its retention in the area of pathology by magnetic force to 
increase the residence time of the agent in the brain capillaries 
and to facilitate their incorporation into the brain parenchyma 
via the blood–brain barrier. Although this concept is not new 
(it was initially proposed in the 1970s by Widder et al),38 it 
has been used only rarely thus far. With current advances 
in the field of biocompatible nanomaterials, this concept 
has become interesting as a strategy for targeting the brain. 
Indeed, drug carriers, theranostic molecules, or even cells 
themselves may be doped with small or ultrasmall iron oxide 
particles that can be tolerated by the host organism and confer 
magnetic properties to the therapeutic agent.39 Such a concept 
has been exploited previously in the treatment of tumors40 and 
for the delivery of gene therapy.41 Moreover, in vitro evidence 
of their feasibility in the treatment of neurological disease has 
been reported,42 although additional in vivo evidence is still 
needed to assess the true potential of magnetic drug delivery 
techniques in this context.
An alternative to magnetic vectorization is the use of 
immunonanoparticles which can also be used to accumulate 
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therapeutic agents in pathological areas. In this case, it is 
imperative to find appropriate molecular markers for the 
targeted tissue to immunovectorize the therapeutic agent. 
For example, proteomic studies performed in our laboratories 
have demonstrated that neurons in the peri-infarct region 
(a key tissue in neuroprotective and neurorepair strategies) 
overexpress HSP72 in cerebral ischemia.23 After preparation, 
we confirmed an increased therapeutic effect of citicoline 
when it was encapsulated in anti-HSP72 immunoliposomes 
compared with its encapsulation in nonvectorized liposomes 
(Figure 6). In this case, accumulation of the theranostic agent 
in the peri-infarct area was achieved in a passive manner 
(whereas magnetic vectorization is an active procedure) using 
molecular recognition between the biomarker overexpressed 
by neurons in the target area (HSP72 protein) and the 
immunovectorized theranostic agent. However, there is no 
reason why both concepts cannot be combined, and future 
work should consider this approach.
Diffuse neurological disorders
Neurodegenerative diseases such as Parkinson’s disease, 
Alzheimer’s disease, or Huntington’s disease, usually 
involve progressive degeneration and death of small niches 
of neurons throughout the encephalic mass, rendering these 
disorders diffuse and difficult to localize. In this case, 
immunovectorization of therapeutic agents against specific 
biomarkers of degenerating cells appears to be a more suitable 
approach than magnetic vectorization. A large amount of 
work has been done to identify appropriate biomarkers for 
early diagnosis of those diseases, but such research usually 
involves screening of blood and cerebrospinal fluid to identify 
target proteins involved in the development of easy-to-handle 
diagnostic tools in the clinical setting.43,44 Most advances in 
the screening of molecular biomarkers for cells inside the 
brain parenchyma have stemmed from the field of molecular 
imaging. Thus, molecules that specifically interact with 
pathological cells in Alzheimer’s disease,45 Parkinson’s 
disease,46 and other neurodegenerative diseases have already 
been described in the literature. Because theranostics is 
considered a natural marriage of molecular imaging and 
drug delivery technologies, the same targets described 
for imaging technologies are also potentially suitable for 
therapeutic purposes.
whole brain disorders
Encephalopathies are a clear example of neurological 
disorders that affect the entire encephalic mass without specific 
localized foci, for which the search for immunovectorization 
targeting of therapeutic/theranostic agents may be futile. 
Thus, more attention should be focused on a strategy for 
boosting access of therapeutic agents to the brain.
Inflammation and activation of the immune system is 
a common process in most neurological disorders. Local 
inflammatory reactions in the brain are characterized by an 
initial increase of blood flow to injured sites and selective 
accumulation of different effector cells from the peripheral 
blood. Such cells, mostly circulating neutrophils, monocytes, 
and locally resident macrophages, together mount a rapid 
inflammatory response characterized by a number of features, 
in particular production of cytokines. Cytokines released into 
the bloodstream stimulate production of chemoattractant 
proteins in the microglia, which drives subsequent infiltration 
of monocytes into the brain.
Thus, in inflammatory processes, the luminal surface 
of the endothelial cell expresses upregulated selectins and 
adhesion molecules that facilitate adhesion of leukocytes 
via corresponding integrins expressed on their surfaces,47 
a process used by cell-mimicking nanoparticles to obtain 
access to the brain.
Given the ability of a number of molecules to attach to 
the surface of theranostic agents, one could attach integrins 
(similar to those expressed by monocytes) to the surfaces of 
nanoparticles to facilitate their incorporation into the brain 
via the blood–brain barrier, exploiting a mechanism similar 
to that used by inflammatory leukocytes. Candidate integrins 
for performing this task include LFA-1 (CD11a/CD18),48 
Mac-1 (CD11b/CD18), and VLA-4 (CD49d/29) as a model 
of “synthetic leukocytes”.
Conclusion
Successful experimental design of a drug treatment for 
neurological disease does not necessarily translate into 
successful therapy in the clinic. The effectiveness of the 
blood–brain barrier is a serious challenge in the delivery 
of therapeutic agents to the brain. A combination of 
knowledge acquired in the fields of drug delivery and 
molecular imaging using common molecular platforms 
has given rise to theranostics, a nanotechnology-based 
discipline that is allowing us to develop efficient tools via 
which drugs can cross the blood–brain barrier and reach 
their therapeutic targets within the brain. Using magnetic 
targeting or immunotargeting of cells and tissues, therapies 
may be made more efficient by focusing their activity in 
pathological tissues and by reducing unnecessary delivery 
of excessive amounts of drugs into the bloodstream. Further, 
the ability to visualize the therapeutic process in vivo will 
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allow adaptation of therapies to the unique characteristics 
of each subject, supporting the concept of personalized 
medicine, which will revolutionize the treatment of patients 
in the coming decades.
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